Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 2
2010 1
2011 1
2012 5
2013 6
2014 5
2015 7
2016 9
2017 6
2018 8
2019 8
2020 9
2021 11
2022 8
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
A Caution Against the Use of C5b-9 Endothelial Assay to Support Eculizumab Therapy: A response to Maritati et al.: "Eculizumab first" in the management of posttransplant thrombotic microangiopathy.
Duineveld C, van de Kar NCAJ, Wetzels JFM. Duineveld C, et al. Among authors: van de kar ncaj. Kidney Int Rep. 2024 Mar 1;9(5):1538. doi: 10.1016/j.ekir.2024.02.1434. eCollection 2024 May. Kidney Int Rep. 2024. PMID: 38707808 Free PMC article. No abstract available.
Modeling complement activation on human glomerular microvascular endothelial cells.
Stevens KH, Baas LM, van der Velden TJAM, Bouwmeester RN, van Dillen N, Dorresteijn EM, van Zuilen AD, Wetzels JFM, Michels MAHM, van de Kar NCAJ, van den Heuvel LP. Stevens KH, et al. Among authors: van de kar ncaj. Front Immunol. 2023 Oct 25;14:1206409. doi: 10.3389/fimmu.2023.1206409. eCollection 2023. Front Immunol. 2023. PMID: 37954621 Free PMC article.
Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE.
Gerogianni A, Baas LM, Sjöström DJ, van de Kar NCAJ, Pullen M, van de Peppel SJ, Nilsson PH, van den Heuvel LP. Gerogianni A, et al. Among authors: van de kar ncaj. Front Immunol. 2023 Oct 26;14:1279612. doi: 10.3389/fimmu.2023.1279612. eCollection 2023. Front Immunol. 2023. PMID: 37954579 Free PMC article.
Narrowing the knowledge gap in atypical HUS.
van de Kar NCAJ, Wetzels JFM. van de Kar NCAJ, et al. Blood. 2023 Oct 19;142(16):1334-1335. doi: 10.1182/blood.2023021474. Blood. 2023. PMID: 37856094 No abstract available.
Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.
Duineveld C, Bouwmeester RN, Wijnsma KL, Bemelman FJ, van der Heijden JW, Berger SP, van den Heuvel LPWJ, van de Kar NCAJ, Wetzels JFM; Dutch aHUS Working Group. Duineveld C, et al. Among authors: van de kar ncaj. Kidney Int Rep. 2023 Jan 19;8(4):715-726. doi: 10.1016/j.ekir.2023.01.016. eCollection 2023 Apr. Kidney Int Rep. 2023. PMID: 37069997 Free PMC article.
Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome.
Ter Avest M, Steenbreker H, Bouwmeester RN, Duineveld C, Wijnsma KL, van den Heuvel LPWJ, Langemeijer SMC, Wetzels JFM, van de Kar NCAJ, Ter Heine R; CUREiHUS Study Group. Ter Avest M, et al. Among authors: van de kar ncaj. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):759-766. doi: 10.2215/CJN.0000000000000145. Epub 2023 Apr 10. Clin J Am Soc Nephrol. 2023. PMID: 36913245
82 results